PND27 ESTIMATING MARGINAL COST-EFFECTIVENESS USING A PERSON-LEVEL NET BENEFITS APPROACH WITH AN APPLICATION TO DISEASE-MODIFYING DRUGS IN MULTIPLE SCLEROSIS

Nov 1, 2007, 00:00 AM
10.1016/S1098-3015(10)65365-X
https://www.valueinhealthjournal.com/article/S1098-3015(10)65365-X/fulltext
Section Title :
Section Order : 523
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65365-X&doi=10.1016/S1098-3015(10)65365-X
HEOR Topics :
Tags :
Regions :